FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2125950103> ?p ?o ?g. }

• W2125950103 abstract "Heavy menstrual bleeding (HMB) is an important cause of ill health in women and it accounts for 12% of all gynaecology referrals in the UK. Heavy menstrual bleeding is clinically defined as greater than or equal to 80 mL of blood loss per menstrual cycle. However, women may complain of excessive bleeding when their blood loss is less than 80 mL. Hysterectomy is often used to treat women with this complaint but medical therapy may be a successful alternative.The intrauterine device was originally developed as a contraceptive but the addition of progestogens to these devices resulted in a large reduction in menstrual blood loss. Case studies of two types of progesterone or progestogen-releasing systems, Progestasert and Mirena, reported reductions of up to 90% and improvements in dysmenorrhoea (pain or cramps during menstruation). Insertion, however, may be regarded as invasive by some women, which affects its acceptability as a treatment. Frequent intermenstrual bleeding and spotting is also likely during the first few months after commencing treatment.To determine the effectiveness, acceptability and safety of progesterone or progestogen-releasing intrauterine devices in achieving a reduction in heavy menstrual bleeding.All randomised controlled trials of progesterone or progestogen-releasing intrauterine devices for the treatment of heavy menstrual bleeding were obtained by electronic searches of The Cochrane Library, the specialised register of MDSG, MEDLINE (1966 to January 2015), EMBASE (1980 to January 2015), CINAHL (inception to December 2014) and PsycINFO (inception to January 2015). Additional searches were undertaken for grey literature and for unpublished trials in trial registers. Companies producing progestogen-releasing intrauterine devices and experts in the field were contacted for information on published and unpublished trials.Randomised controlled trials in women of reproductive age treated with progesterone or progestogen-releasing intrauterine devices versus no treatment, placebo, or other medical or surgical therapy for heavy menstrual bleeding within primary care, family planning or specialist clinic settings were eligible for inclusion. Women with postmenopausal bleeding, intermenstrual or irregular bleeding, or pathological causes of heavy menstrual bleeding were excluded.Potential trials were independently assessed by at least two review authors. The review authors extracted the data independently and data were pooled where appropriate. Risk ratios (RRs) were estimated from the data for dichotomous outcomes and mean differences (MD) for continuous outcomes. The primary outcomes were reduction in menstrual blood loss and satisfaction; in addition, rate of adverse effects, changes in quality of life, failure of treatment and withdrawal from treatment were also assessed.We included 21 RCTs (2082 women). The included trials mostly assessed the levonorgestrel-releasing intrauterine device (LNG IUS) (no conclusions could be reached from one small study assessing Progestasert which was discontinued in 2001) and so conclusions are based only on LNG IUS. Comparisons were made with placebo, oral medical treatment, endometrial destruction techniques and hysterectomy. Ratings for the overall quality of the evidence for each comparison ranged from very low to high. Limitations in the evidence included inadequate reporting of study methods and inconsistency.Seven studies compared the LNG IUS with oral medical therapy: either norethisterone acetate (NET) administered over most of the menstrual cycle, medroxyprogesterone acetate (MPA) (administered for 10 days), the oral contraceptive pill, mefenamic acid or usual medical treatment where participants could choose the oral treatment that was most suitable. The LNG IUS was more effective at reducing HMB as measured by the alkaline haematin method (MD 66.91 mL, 95% CI 42.61 to 91.20; two studies, 170 women; I(2) = 81%, low quality evidence) or by Pictorial Bleeding Assessment Chart (PBAC) scores (MD 55.05, 95% CI 27.83 to 82.28; three studies, 335 women; I(2) = 79%, low quality evidence), improving quality of life and a greater number of women continued with their treatment at two years when compared with oral treatment. Although substantial heterogeneity was identified for the bleeding outcomes, the direction of effect consistently favoured the LNG IUS. There was insufficient evidence to reach conclusions on satisfaction. Minor adverse effects (such as pelvic pain, breast tenderness and ovarian cysts) were more common with the LNG IUS.Ten studies compared the LNG IUS with endometrial destruction techniques: three with transcervical resection, one with rollerball ablation and six with thermal balloon ablation. Evidence was inconsistent and very low quality with respect to reduction in bleeding outcomes and satisfaction was comparable between treatments (low and moderate quality evidence). Improvements in quality of life were experienced with both types of treatment. Minor adverse events were more common with the LNG IUS overall, but it appeared more cost effective compared to thermal ablation within a two-year time frame in one study.Three studies compared the LNG IUS with hysterectomy. The LNG IUS was not as successful at reducing HMB as hysterectomy (high quality evidence). The women in these studies reported improved quality of life, regardless of treatment. In spite of the high rate of surgical treatment in those having LNG IUS within 10 years, the LNG IUS was more cost effective than hysterectomy.The levonorgestrel-releasing intrauterine device (LNG IUS) is more effective than oral medication as a treatment for heavy menstrual bleeding (HMB). It is associated with a greater reduction in HMB, improved quality of life and appears to be more acceptable long term but is associated with more minor adverse effects than oral therapy.When compared to endometrial ablation, it is not clear whether the LNG IUS offers any benefits with regard to reduced HMB and satisfaction rates and quality of life measures were similar. Some minor adverse effects were more common with the LNG IUS but it appeared to be more cost effective than endometrial ablation techniques.The LNG IUS was less effective than hysterectomy in reducing HMB. Both treatments improved quality of life but the LNG IUS appeared more cost effective than hysterectomy for up to 10 years after treatment." @default.
• W2125950103 created "2016-06-24" @default.
• W2125950103 creator A5003873270 @default.
• W2125950103 creator A5009731454 @default.
• W2125950103 creator A5030557539 @default.
• W2125950103 date "2015-04-30" @default.
• W2125950103 modified "2023-10-01" @default.
• W2125950103 title "Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding" @default.
• W2125950103 cites W106328369 @default.
• W2125950103 cites W1529006820 @default.
• W2125950103 cites W1606787363 @default.
• W2125950103 cites W1863072841 @default.
• W2125950103 cites W1966995863 @default.
• W2125950103 cites W1974717633 @default.
• W2125950103 cites W1975560573 @default.
• W2125950103 cites W1978711334 @default.
• W2125950103 cites W1985224691 @default.
• W2125950103 cites W1986765871 @default.
• W2125950103 cites W1987160533 @default.
• W2125950103 cites W1987409154 @default.
• W2125950103 cites W1988697850 @default.
• W2125950103 cites W1989766586 @default.
• W2125950103 cites W1997276321 @default.
• W2125950103 cites W2000227192 @default.
• W2125950103 cites W2002100432 @default.
• W2125950103 cites W2002216387 @default.
• W2125950103 cites W2007749187 @default.
• W2125950103 cites W2009186106 @default.
• W2125950103 cites W2012165536 @default.
• W2125950103 cites W2014551224 @default.
• W2125950103 cites W2015496453 @default.
• W2125950103 cites W2018502455 @default.
• W2125950103 cites W2019198329 @default.
• W2125950103 cites W2023952454 @default.
• W2125950103 cites W2031785143 @default.
• W2125950103 cites W2032832595 @default.
• W2125950103 cites W2033128963 @default.
• W2125950103 cites W2036176489 @default.
• W2125950103 cites W2039697576 @default.
• W2125950103 cites W2042215703 @default.
• W2125950103 cites W2042374015 @default.
• W2125950103 cites W2045277407 @default.
• W2125950103 cites W2045982133 @default.
• W2125950103 cites W2046628595 @default.
• W2125950103 cites W2053347706 @default.
• W2125950103 cites W2054776513 @default.
• W2125950103 cites W2055152822 @default.
• W2125950103 cites W2065116919 @default.
• W2125950103 cites W2066275703 @default.
• W2125950103 cites W2068294052 @default.
• W2125950103 cites W2068455631 @default.
• W2125950103 cites W2069748871 @default.
• W2125950103 cites W2071704326 @default.
• W2125950103 cites W2081092254 @default.
• W2125950103 cites W2083325296 @default.
• W2125950103 cites W2090979444 @default.
• W2125950103 cites W2092026322 @default.
• W2125950103 cites W2093248698 @default.
• W2125950103 cites W2094514543 @default.
• W2125950103 cites W2100901575 @default.
• W2125950103 cites W2108814154 @default.
• W2125950103 cites W2109718964 @default.
• W2125950103 cites W2112591684 @default.
• W2125950103 cites W2112729447 @default.
• W2125950103 cites W2114807084 @default.
• W2125950103 cites W2115544934 @default.
• W2125950103 cites W2117722672 @default.
• W2125950103 cites W2123592959 @default.
• W2125950103 cites W2129059159 @default.
• W2125950103 cites W2129635652 @default.
• W2125950103 cites W2130722794 @default.
• W2125950103 cites W2135315003 @default.
• W2125950103 cites W2152367884 @default.
• W2125950103 cites W2153217129 @default.
• W2125950103 cites W2155352577 @default.
• W2125950103 cites W2156027325 @default.
• W2125950103 cites W2156504049 @default.
• W2125950103 cites W2159787422 @default.
• W2125950103 cites W2177758634 @default.
• W2125950103 cites W2313905864 @default.
• W2125950103 cites W2318604585 @default.
• W2125950103 cites W2418241203 @default.
• W2125950103 cites W2955760119 @default.
• W2125950103 cites W4236594144 @default.
• W2125950103 cites W4243609801 @default.
• W2125950103 cites W4385790955 @default.
• W2125950103 doi "https://doi.org/10.1002/14651858.cd002126.pub3" @default.
• W2125950103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25924648" @default.
• W2125950103 hasPublicationYear "2015" @default.
• W2125950103 type Work @default.
• W2125950103 sameAs 2125950103 @default.
• W2125950103 citedByCount "137" @default.
• W2125950103 countsByYear W21259501032012 @default.
• W2125950103 countsByYear W21259501032013 @default.
• W2125950103 countsByYear W21259501032014 @default.
• W2125950103 countsByYear W21259501032015 @default.
• W2125950103 countsByYear W21259501032016 @default.
• W2125950103 countsByYear W21259501032017 @default.
• W2125950103 countsByYear W21259501032018 @default.
• W2125950103 countsByYear W21259501032019 @default.

• next